GlobeNewsWire
13 Jan 2026, 21:15 UTC · 43w ago
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
Impact · against what's priced in
Solid Biosciences (SLDB) is showing positive operational momentum across its clinical pipeline and platform licensing. The progression of SGT-003 toward a Phase 3 trial and the pursuit of an accelerated approval pathway represent significant de-risking events for its lead candidate.
- SLDB+0.60
No priced-in read yet





